KLOW is the GLOW blend — BPC-157, TB-500, and GHK-Cu — plus KPV, a tripeptide studied for anti-inflammatory signaling. It's the broadest of the three pre-blended stacks on this site, and the only one that adds an inflammatory-pathway mechanism to the repair-and-remodeling base the other two share.
The Fourth Peptide: KPV
KPV (Lys-Pro-Val) is the C-terminal tripeptide fragment of alpha-MSH, studied independently of alpha-MSH's pigmentation and appetite effects. Its own product guide on this site covers its full profile; the summary relevant to KLOW is its mechanism of action.
What the Literature Shows
A 2008 study in Gastroenterology found that KPV's anti-inflammatory effect is PepT1-mediated — the tripeptide is taken up by the PepT1 transporter in intestinal epithelial and immune cells, where nanomolar concentrations inhibit NF-κB and MAP kinase inflammatory signaling and reduce pro-inflammatory cytokine secretion. In the same study, oral KPV reduced the severity of colitis in two separate mouse models.
Why Add It to GLOW
BPC-157, TB-500, and GHK-Cu are studied for tissue repair and matrix remodeling — three angles on the same broad process. KPV's NF-κB and cytokine-signaling research sits on a separate axis: inflammatory regulation and gut-lining research, distinct from the repair mechanisms of the other three. Researchers extending Glow to Klow are typically adding inflammatory-pathway coverage the base three peptides don't address, not intensifying the repair effect itself.
What's not established: the four-peptide combination hasn't been studied as a unit. Each compound's evidence, including KPV's, comes from studies where it was administered alone.
For the full KPV profile, see the KPV research guide; for BPC-157, TB-500, and GHK-Cu, see the GLOW Blend guide.
Sourcing KLOW
View the KLOW Stack product page →Frequently Asked Questions
Is KLOW better than GLOW, or just different?
Different, not strictly better — they share the same BPC-157/TB-500/GHK-Cu base. KPV's evidence is specifically about NF-κB inflammatory signaling and gut-lining research, a mechanism the other three peptides don't address. Whether that's relevant depends on what the research protocol is actually studying.
References
1. Dalmasso G, et al. "PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation." Gastroenterology, 2008. PubMed
This article contains affiliate links. Aura Protocols may earn a commission if you purchase through these links at no additional cost to you. All compounds are for research use only.